As EGFR is known to promote proliferation of cancer cells [23], dual targeting of VEGF with bevacizumab and EGFR with erlotinib was considered to be a logical treatment approach for advanced HCC. This evidence concerns the gene VEGFA and hepatocellular carcinoma.